Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Net Change in Cash

The Net Change in Cash of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 8, 2026 is -517.56 M CNY. In the previous year, Net Change in Cash was -56.28 M CNY — a change of 819.63% (lower).

Net Change in Cash

-517.56 MCNY

YoY

819.63%

Last updated:

Net Change in Cash of Vcanbio Cell & Gene Engineering Corp is 2025 -517.56 M CNY. Net Change in Cash of Vcanbio Cell & Gene Engineering Corp was 2024 -56.28 M CNY. It decreases by 819.63% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
109.31 M CNY
Jan 1, 2019
46.45 M CNY
Jan 1, 2020
428.63 M CNY
Jan 1, 2021
129.75 M CNY
Jan 1, 2022
191.10 M CNY
Jan 1, 2023
200.02 M CNY
Jan 1, 2024
-56.28 M CNY
Jan 1, 2025
-517.56 M CNY
The Vcanbio Cell & Gene Engineering Corp Net Change in Cash history
YEARNet Change in CashYoY
-517.56 MCNY+819.63%
-56.28 MCNY-128.14%
200.02 MCNY+4.67%
191.10 MCNY+47.28%
129.75 MCNY-69.73%
428.63 MCNY+822.77%
46.45 MCNY-57.51%
109.31 MCNY+648.12%
14.61 MCNY-104.96%
-294.85 MCNY-235.06%
218.31 MCNY-143.95%
-496.71 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Net Change in Cash of Vcanbio Cell & Gene Engineering Corp is -517.56 M CNY in 2025.

Net Change in Cash of Vcanbio Cell & Gene Engineering Corp changed from -56.28 M CNY to -517.56 M CNY, representing a 819.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp